1. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: Results of a prospective, randomized, multicentre trial
- Author
-
Basoli, Antonio, Chirletti, Piero, Paolo, Mazzocchi, Vincenzo, Speranza, Lezoche, E., Guerrieri, M., Marrano, D., Minni, F., Giulini, S. M., Nodari, F., Brotzu, G., Loddo, P., Latteri, F., Scuderi, Gianluca, Rodolico, G., Cavallaro, L., Donini, I., Sortini, A., Tonelli, F., Spini, S., Natale, C., Musto, V., Vio, A., Verdecchia, G., Morgagni, D., Mariani, L., Montefusco, A., Gerosa, E., Tiberio, G., Nardone, A., Mazzeo, F., Benassai, G., D'Amico, D., Tropea, A., Piervittori, M., Becelli, S., Cazzaniga, M., Stagnitti, F., Crucitti, F., Pacelli, F., Gargiulo, A., Panichi, Giovanni, DI ROSA, Roberta, Porzio, R., Lombardi, U., Stipa, V., Chirletti, P., De Anna, D., Pisano, I., Armenio, S., Salvestrini, E., Baglioni, A., Iafrate, G., Donadio, F., Paron, L., Saccia, A., Di Girolamo, P., A., Basoli, E. Z., Meli, P., Mazzocchi, V., Speranza, E., Lezoche, M., Guerrieri, D., Marrano, F., Minni, S. M., Giulini, F., Nodari, G., Brotzu, P., Loddo, F., Latteri, G., Scuderi, G., Rodolico, L., Cavallaro, I., Donini, A., Sortini, F., Tonelli, S., Spini, C., Natale, V., Musto, A., Vio, G., Verdecchia, D., Morgagni, L., Mariani, A., Montefusco, E., Gerosa, G., Tiberio, Nardone, GERARDO ANTONIO PIO, F., Mazzeo, Benassai, Giacomo, D., Damico, A., Tropea, M., Piervittori, S., Becelli, M., Cazzaniga, F., Stagnitti, F., Crucitti, F., Pacelli, A., Gargiulo, G., Panichi, R., Dirosa, R., Porzio, U., Lombardi, V., Stipa, P., Chirletti, D., Deanna, I., Pisano, S., Armenio, E., Salvestrini, A., Baglioni, G., Iafrate, F., Donadio, L., Paron, A., Saccia, and P., Digirolamo
- Subjects
Adult ,Male ,Microbiology (medical) ,Imipenem ,Meropenem ,law.invention ,Randomized controlled trial ,law ,Abdomen ,polycyclic compounds ,medicine ,Humans ,Protease Inhibitors ,Prospective Studies ,Infusions, Intravenous ,Prospective cohort study ,APACHE ,Aged ,General Immunology and Microbiology ,Cilastatin ,business.industry ,Imipenem/cilastatin ,Bacterial Infections ,General Medicine ,Middle Aged ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,Anti-Bacterial Agents ,Clinical trial ,Treatment Outcome ,Infectious Diseases ,Tolerability ,Anesthesia ,Female ,Thienamycins ,business ,medicine.drug - Abstract
30 citazioni su Scopus. 46 citazioni su GoogleScholar. ------ http://www.scopus.com/record/display.url?eid=2-s2.0-0347771343&origin=resultslist&sort=plf-f&src=s&sid=1BklTwBDkRxWaxt9FLi7YAz%3a70&sot=aut&sdt=a&sl=37&s=AU-ID%28%22Benassai%2c+Giacomo%22+6602920646%29&relpos=11&relpos=11&searchTerm=AU-ID(\"Benassai, Giacomo\" 6602920646) ------ An open-label prospective, randomized, parallel multicentre study was undertaken to compare the efficacy and tolerability of 1.5 g/day intravenous imipenem/cilastatin with 3 g/day intravenous meropenem in the treatment of intra-abdominal infections, A total of 287 patients mere enrolled; 201 patients, divided between the 2 treatment groups, were evaluable. Clinical outcome, bacteriological outcome, untoward microbiological effects, and clinical and laboratory adverse experiences mere evaluated, 98% of patients receiving imipenem/cilastatin therapy mere cured, with 96% showing eradication of infection, 95% of those on meropenem mere cured, with 98% showing eradication. These differences in clinical and bacteriological outcome between the 2 treatments were not statistically significant, Two patients receiving imipenem/cilastatin and 5 receiving meropenem had untoward microbiological effects. There mas a 0.7% frequency (1/139 patients) of possibly or probably drug-related clinical or laboratory adverse experiences with imipenem/cilastatin and a 2.7% frequency (4/148) with meropenem, The mean time to defervescence was significantly less for patients in the imipenem/cilastatin treatment group than for those receiving meropenem. This study shows that 1.5 g/day of imipenem/cilastatin is equivalent to 3.0 g/day meropenem in clinical and bacteriological outcome, as well as in incidence of side effects.
- Published
- 1997